Name | Number of supported studies | Average coverage | |
---|---|---|---|
T follicular helper cell | 5 studies | 45% ± 14% | |
CD8-positive, alpha-beta T cell | 5 studies | 24% ± 9% | |
exhausted T cell | 3 studies | 40% ± 6% | |
regulatory T cell | 3 studies | 19% ± 2% | |
T cell | 3 studies | 21% ± 5% |
Insufficient scRNA-seq data for expression of PDCD1 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
lung | 100% | 184.68 | 577 / 578 | 74% | 5.60 | 852 / 1155 |
thymus | 98% | 169.87 | 639 / 653 | 54% | 7.14 | 328 / 605 |
stomach | 89% | 90.28 | 321 / 359 | 59% | 4.13 | 169 / 286 |
uterus | 71% | 37.20 | 120 / 170 | 63% | 5.39 | 289 / 459 |
kidney | 79% | 73.00 | 70 / 89 | 53% | 5.65 | 478 / 901 |
intestine | 68% | 124.63 | 660 / 966 | 52% | 3.44 | 272 / 527 |
breast | 73% | 51.02 | 336 / 459 | 46% | 3.29 | 512 / 1118 |
esophagus | 62% | 41.82 | 899 / 1445 | 55% | 3.07 | 101 / 183 |
prostate | 87% | 79.14 | 212 / 245 | 27% | 1.21 | 137 / 502 |
bladder | 62% | 66.33 | 13 / 21 | 47% | 3.12 | 235 / 504 |
lymph node | 0% | 0 | 0 / 0 | 100% | 62.31 | 29 / 29 |
spleen | 100% | 684.40 | 241 / 241 | 0% | 0 | 0 / 0 |
peripheral blood | 97% | 656.93 | 900 / 929 | 0% | 0 | 0 / 0 |
skin | 32% | 15.57 | 570 / 1809 | 64% | 11.90 | 300 / 472 |
heart | 89% | 294.93 | 766 / 861 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 89% | 12.14 | 40 / 45 |
adipose | 89% | 91.15 | 1070 / 1204 | 0% | 0 | 0 / 0 |
pancreas | 23% | 9.49 | 76 / 328 | 55% | 4.09 | 98 / 178 |
ovary | 32% | 14.98 | 57 / 180 | 41% | 2.19 | 176 / 430 |
liver | 39% | 16.47 | 88 / 226 | 31% | 3.84 | 127 / 406 |
adrenal gland | 50% | 24.18 | 128 / 258 | 11% | 0.42 | 25 / 230 |
blood vessel | 43% | 33.79 | 579 / 1335 | 0% | 0 | 0 / 0 |
brain | 24% | 13.17 | 635 / 2642 | 8% | 0.38 | 59 / 705 |
eye | 0% | 0 | 0 / 0 | 15% | 1.68 | 12 / 80 |
muscle | 5% | 2.33 | 40 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_1902482 | Biological process | regulatory T cell apoptotic process |
GO_0006915 | Biological process | apoptotic process |
GO_0002250 | Biological process | adaptive immune response |
GO_0050868 | Biological process | negative regulation of T cell activation |
GO_0002644 | Biological process | negative regulation of tolerance induction |
GO_0002903 | Biological process | negative regulation of B cell apoptotic process |
GO_0050777 | Biological process | negative regulation of immune response |
GO_0002841 | Biological process | negative regulation of T cell mediated immune response to tumor cell |
GO_0070234 | Biological process | positive regulation of T cell apoptotic process |
GO_0050776 | Biological process | regulation of immune response |
GO_0001783 | Biological process | B cell apoptotic process |
GO_0006959 | Biological process | humoral immune response |
GO_0009897 | Cellular component | external side of plasma membrane |
GO_0005886 | Cellular component | plasma membrane |
GO_0038023 | Molecular function | signaling receptor activity |
GO_0005515 | Molecular function | protein binding |
Gene name | PDCD1 |
Protein name | Programmed cell death 1 (Programmed cell death protein 1) Programmed cell death protein 1 (Protein PD-1) (hPD-1) (CD antigen CD279) Programmed cell death 1 protein |
Synonyms | PD1 |
Description | FUNCTION: Inhibitory receptor on antigen activated T-cells that plays a critical role in induction and maintenance of immune tolerance to self . Delivers inhibitory signals upon binding to ligands CD274/PDCD1L1 and CD273/PDCD1LG2 . Following T-cell receptor (TCR) engagement, PDCD1 associates with CD3-TCR in the immunological synapse and directly inhibits T-cell activation (By similarity). Suppresses T-cell activation through the recruitment of PTPN11/SHP-2: following ligand-binding, PDCD1 is phosphorylated within the ITSM motif, leading to the recruitment of the protein tyrosine phosphatase PTPN11/SHP-2 that mediates dephosphorylation of key TCR proximal signaling molecules, such as ZAP70, PRKCQ/PKCtheta and CD247/CD3zeta (By similarity). .; FUNCTION: The PDCD1-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and escape destruction by the immune system, thereby facilitating tumor survival . The interaction with CD274/PDCD1L1 inhibits cytotoxic T lymphocytes (CTLs) effector function . The blockage of the PDCD1-mediated pathway results in the reversal of the exhausted T-cell phenotype and the normalization of the anti-tumor response, providing a rationale for cancer immunotherapy . . |
Accessions | E7ER21 A0A0M3M0G7 ENST00000630230.1 Q15116 ENST00000334409.10 ENST00000343705.3 ENST00000630560.1 H0Y2W6 ENST00000418831.1 ENST00000618185.3 |